ClinicalTrials.Veeva
Menu

Find clinical trials for Kidney Disease in Madrid, MD

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Kidney Diseases
Chronic Renal Insufficiency
Chronic Kidney Failure
IGA Glomerulonephritis
Renal Insufficiency
Renal Cell Carcinoma
Kidney Cancer

Kidney Disease trials near Madrid, MD, ESP:

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney...

Enrolling
Complement-mediated Kidney Disease
IgA Nephropathy (IgAN)
Drug: ADX-038 Dose Level 1
Drug: ADX-038 Dose Level 2

Phase 2

ADARx Pharmaceuticals

Madrid, Spain and 24 other locations

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common genetic cause of kidney disease that caus...

Enrolling
Autosomal Dominant Polycystic Kidney Disease
Drug: ABBV-CLS-628
Drug: Placebo

Phase 2

AbbVie
AbbVie

Madrid, Spain and 74 other locations

people who have a kidney disease called autosomal dominant polycystic kidney disease (ADPKD)....

Enrolling
Kidney Disease
Drug: Placebo matching GSK4771261
Drug: GSK4771261

Phase 1

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Madrid, Spain and 13 other locations

Roxadustat is a licensed medicine to treat anemia in adults with chronic kidney disease (CKD). Anemia is a low level of red blood c...

Enrolling
Chronic Kidney Disease
Renal Anemia
Drug: Roxadustat

Phase 3

Astellas
Astellas

Madrid, Spain and 46 other locations

tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney...

Enrolling
Proteinuric Kidney Disease
Drug: VX-147
Drug: Placebo

Phase 2, Phase 3

Vertex Pharmaceuticals
Vertex Pharmaceuticals

Madrid, Spain and 330 other locations

with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Part...

Enrolling
Chronic Kidney Disease
Atherosclerosis Cardiovascular Disease
Drug: Orforglipron
Drug: Placebo

Phase 3

Lilly
Lilly

Boadilla del Monte, Spain and 561 other locations

to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney...

Active, not recruiting
Chronic Kidney Disease With High Proteinuria
Drug: Dapagliflozin
Drug: Zibotentan/Dapagliflozin

Phase 3

AstraZeneca
AstraZeneca

Madrid, Spain and 297 other locations

The study evaluates the safety of different doses of a new medicine called NNC0519 0130. It also looks into how the medicine may improve kidney...

Enrolling
Chronic Kidney Disease
Drug: Placebo
Drug: Semaglutide

Phase 2

Novo Nordisk
Novo Nordisk

Madrid, Spain and 135 other locations

New

The purpose of this study is to assess the safety, tolerability, pharmacokinetic, and efficacy of surovatamig administered by subcutaneous injection...

Enrolling
Primary Membranous Nephropathy
Drug: Surovatamig

Phase 2

AstraZeneca
AstraZeneca

Madrid, Spain and 20 other locations

and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney...

Enrolling
Chronic Kidney Disease and Hypertension
Drug: Baxdrostat/dapagliflozin
Drug: Placebo/dapagliflozin

Phase 3

AstraZeneca
AstraZeneca

Majadahonda, Spain and 744 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems